Welcome to our dedicated page for ADMS news (Ticker: ADMS), a resource for investors and traders seeking the latest updates and insights on ADMS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ADMS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ADMS's position in the market.
Adamas Pharmaceuticals (Nasdaq: ADMS) announced the appointment of Spyros Papapetropoulos to its Board of Directors, effective immediately. Papapetropoulos brings over 20 years of experience in neurology, having previously held leadership roles at Acadia, Teva, Pfizer, and others. This change comes with the retirement of Ivan Lieberburg, who served since 2004 and contributed significantly to multiple NDA submissions. Chairman David L. Mahoney and CEO Neil F. McFarlane expressed optimism about the future, highlighting Papapetropoulos's expertise in neurodegenerative diseases as a valuable asset.
Adamas Pharmaceuticals (Nasdaq: ADMS) has announced that CEO Neil F. McFarlane will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. This event aims to discuss the company's commitment to developing innovative medicines for neurological diseases.
The pre-recorded chat will be available for replay starting November 23, 2020, for 30 days, accessible on the Adamas investor relations website.
Adamas Pharmaceuticals (Nasdaq: ADMS) announced the grant of stock options and restricted stock units to three new employees, totaling 45,000 shares at an exercise price of $3.45. This price reflects the closing trading amount on November 6, 2020. The awarded stock options and restricted units will vest over four years and were issued under the 2016 Inducement Plan, approved by the board in March 2016. This move is aimed at attracting new talent to support the company’s growth in developing neurological disease therapies.
Adamas Pharmaceuticals (ADMS) reported strong third quarter 2020 results with total revenues of $20.2 million, a 45% increase from $13.9 million the previous year. GOCOVRI product sales reached $19.0 million, up 36% year-over-year, supported by 7,930 paid prescriptions, a 19% increase. R&D expenses significantly decreased to $2.3 million from $6.0 million. However, the net loss was $11.9 million, down from a loss of $27.6 million in Q3 2019. The company updated its full-year expense guidance, lowering R&D expectations to $9 million - $11 million.
Adamas Pharmaceuticals (Nasdaq: ADMS) will report its Q3 2020 financial results on November 5, 2020, after market close. Following the financial report, a conference call will be held at 4:30 PM ET to discuss results and provide corporate updates. Investors can access the call by dialing (844) 215-3280 (U.S.) or (484) 747-6383 (international) using Conference ID: 1578986. A live webcast will be available on the Adamas website and will be accessible for replay until December 5, 2020.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) has granted stock options for 161,000 shares and restricted stock units for 80,500 shares to four new employees. The stock options, priced at $4.45 per share, will vest over four years. This initiative is part of the 2016 Inducement Plan approved by the board to attract talent.
This move aims to strengthen the company’s workforce as it continues to focus on delivering innovative treatments for neurological diseases.
Adamas Pharmaceuticals (Nasdaq: ADMS) has announced the granting of stock options and restricted stock units to two new employees, totaling 269,250 shares at an exercise price of $5.12 each, along with 2,125 restricted stock units. These awards will vest over four years and are part of the 2016 Inducement Plan, aimed at attracting new talent. The plan complies with Nasdaq rules for equity grants. Adamas continues its focus on innovative treatments for neurological diseases, notably its FDA-approved drug GOCOVRI for Parkinson's disease-related dyskinesia.
Adamas Pharmaceuticals (Nasdaq: ADMS) announced that CEO Neil F. McFarlane will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15 at 12:30 pm ET. The presentation will be available via live webcast on the company's investor relations webpage, with a replay accessible for 30 days post-event. Adamas focuses on developing innovative therapies for neurological diseases, having launched GOCOVRI®, the first FDA-approved treatment for dyskinesia in Parkinson’s patients, in 2018.
Adamas Pharmaceuticals has announced the grant of stock options to three new employees, totaling 36,000 shares at an exercise price of $3.78, along with 18,000 restricted stock units. These options will vest over four years as part of the 2016 Inducement Plan, which aims to attract talent to the company. This moves comes as Adamas continues its focus on developing therapies for neurological diseases, including their FDA-approved medication, GOCOVRI, designed to treat dyskinesia in Parkinson's patients.
Adamas Pharmaceuticals reported a strong second quarter 2020 with GOCOVRI sales reaching $18.0 million, a 41% increase from the previous year. Total revenue was $18.8 million, reflecting growth attributed to rising prescriptions and new royalty income. Despite a net loss of $10.6 million, down from $24.9 million year-over-year, the company's R&D expenses decreased significantly to $2.6 million. The FDA accepted a supplemental NDA for GOCOVRI for Parkinson's disease treatment, with a decision expected by February 1, 2021.
